Figure 2.
Figure 2. Trends of peripheral counts through treatment. Absolute lymphocyte count (A), hemoglobin (B), and platelet count (C) in the peripheral blood before and after treatment are shown in the y-axis; x-axis represents timeline in days. The time points at which alemtuzumab and tofacitinib were added are indicated by arrows. The time points at which the patient received red blood cell transfusions for panel B and platelet transfusions for panel C are indicated by blue arrows. Hb, hemoglobin; PB, peripheral blood; Plt, platelet.

Trends of peripheral counts through treatment. Absolute lymphocyte count (A), hemoglobin (B), and platelet count (C) in the peripheral blood before and after treatment are shown in the y-axis; x-axis represents timeline in days. The time points at which alemtuzumab and tofacitinib were added are indicated by arrows. The time points at which the patient received red blood cell transfusions for panel B and platelet transfusions for panel C are indicated by blue arrows. Hb, hemoglobin; PB, peripheral blood; Plt, platelet.

Close Modal

or Create an Account

Close Modal
Close Modal